Genentech Provides Update on Phase III Verona Study

Genentech and AbbVie's Phase III VERONA study of Venclexta in combination with azacitidine for previously untreated higher-risk myelodysplastic syndromes (MDS) failed to meet its primary endpoint of overall survival. The safety profile was consistent with known risks, and full data will be presented in 2025; however, these results do not impact Venclexta's currently approved indications or ongoing studies.

Analysis

Genentech (a member of the Roche Group, RHHBY) and AbbVie (ABBV) have reported a significant setback in their oncology pipeline, as the AbbVie-led Phase III VERONA study evaluating Venclexta (venetoclax) combined with azacitidine for previously untreated higher-risk myelodysplastic syndromes (MDS) failed to meet its primary endpoint of overall survival. This outcome from the global study, which enrolled approximately 500 patients, curtails immediate prospects for expanding Venclexta's use into this specific MDS patient segment. While the companies stated the safety profile was consistent with the known risks of the individual drugs and no new safety concerns were identified—a minor positive—the inability to demonstrate an overall survival benefit is paramount. Crucially, this trial failure does not impact Venclexta's currently approved indications for chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia, nor does it affect other ongoing studies for the drug. Full data from the VERONA study are expected to be presented at a medical conference in 2025, which will provide a more detailed view, though the top-line result is definitive. The mildly negative sentiment (-0.3) and low market impact score (0.3) associated with this news suggest that while disappointing, the market may not have heavily factored in success for this particular indication, or views the impact as limited given the drug's existing approvals and the companies' diversified portfolios.

Key Decisions for Investors

• Investors should adjust expectations for Venclexta's growth trajectory for both AbbVie (ABBV) and Roche (RHHBY), as the failure in the higher-risk MDS VERONA trial removes a potential near-term expansion opportunity.
• It is prudent to await the full data presentation in 2025 for deeper insights, though the likelihood of regulatory approval for this indication based on the current outcome is low.
• Focus should remain on Venclexta's performance in its approved indications (CLL, SLL, AML), which are unaffected by this specific trial result, and assess the companies' broader oncology pipelines for future growth drivers.